Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

CompletedOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Neoplasms, Unknown PrimaryCUPMetastatic DiseasePoorly Differentiated AdenocarcinomaPoorly Differentiated CarcinomaSquamous Carcinoma Poorly Differentiated
Trial Locations (1)

02141

Foundation Medicine, Inc, Cambridge

All Listed Sponsors
collaborator

Rush University Medical Center

OTHER

collaborator

Stormont-Vail Healthcare

UNKNOWN

collaborator

Jefferson Medical College of Thomas Jefferson University

OTHER

collaborator

The Cleveland Clinic

OTHER

collaborator

Sparrow Health System

OTHER

collaborator

Cancer & Hematology Centers of Western Michigan (CHCWM)

UNKNOWN

collaborator

Allegheny Health Network

OTHER

collaborator

St. Luke's Hospital and Health Network, Pennsylvania

OTHER

collaborator

Solano Hematology Oncology

UNKNOWN

collaborator

Horizon Oncology Center

UNKNOWN

collaborator

Comprehensive Blood and Cancer Center

OTHER

collaborator

Lancaster Cancer Center

OTHER

collaborator

Western Maryland Health Center

UNKNOWN

collaborator

Valley Medical Oncology

UNKNOWN

collaborator

Cape Fear Valley Health System

OTHER

collaborator

Tri-County Hematology Oncology

UNKNOWN

collaborator

Hematology & Oncology Associates

UNKNOWN

collaborator

Broome Oncology

UNKNOWN

collaborator

Orchard Healthcare

UNKNOWN

collaborator

Ashland Bellefonte Cancer Center

UNKNOWN

collaborator

Tennessee Cancer Specialists

UNKNOWN

collaborator

North Shore Hematology Oncology

UNKNOWN

collaborator

Good Samaritan

UNKNOWN

collaborator

Zangmeister Cancer Center

UNKNOWN

collaborator

Watson clinic

UNKNOWN

collaborator

Oncology Consultants

UNKNOWN

collaborator

Oncology Hematology Care

UNKNOWN

collaborator

Northern Westchester Hospital

OTHER

collaborator

Peter MacCallum Cancer Center Trials Unit

UNKNOWN

lead

Foundation Medicine

INDUSTRY

NCT02628379 - Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary | Biotech Hunter | Biotech Hunter